



Available online at
ScienceDirect
www.sciencedirect.com

Elsevier Masson France
EM|consulte
www.em-consulte.com/en



Correspondence

Reply to the comment of Mourgues et al., 2012. American guidelines for the management of gout as seen by general practitioners



We have read with interest the comments from Mourgues et al., from Clermont-Ferrand university [1], regarding our recent publication on EULAR recommendations in a large French cohort of patients with gout managed in private practice, both by general practitioners and rheumatologists [2].

Indeed it is worthy to first indicate that our goal was to compare the French practice in 2008–2009 with the first EULAR recommendations published in 2006 [3] and revised in 2016 [4]. Indeed Mourgues et al. referred to the 2012 ACR recommendations, which were not published yet at time of GOSPEL cohort [5].

When comparing all recommendations published over the last decade [6], differences were not so striking but the knowledge on gout epidemiology, basic research, new tools (ultrasonography, dual energy CT scan), new drugs such as febuxostat not marketed in 2008, canakinumab in development at that time, etc, has increased exponentially. Anyway, the Gospel study, referred on the EULAR 2006 guidelines, is still useful by providing feedback on global physician knowledge and usual management of standard of care drugs such as colchicine and allopurinol. These two drugs help a lot when used appropriately.

As indicated by Mourgues et al, following their large survey by mail of 505 GPs in the Auvergne region, looked at the ACR 2012 recommendations [7]. Thanks to their good practice to start as soon as possible non-steroidal anti-inflammatory drugs (NSAIDs) or/and colchicine. We want to recall that in our GOSPEL survey, misuse of colchicine was noticed, with high daily dosage > 4 mg/d in that old time, and no dosage adaptation in elderly patients and in patients with chronic kidney diseases [8]. Our colleagues do not provide insights on that key point since colchicine is the first anti-inflammatory drug used in gout flare; indeed in the 2012 ACR recommendations, colchicine has made a “retour en force” after the clinical trial by Terkeltaub et al, comparing low dose colchicine at Day 1 (1.8 mg) versus usual US high doses (4.8 mg/d). Following these recommendations, nowadays colchicine is used at that dosage. In France, the maximal daily dosage of colchicine is 3.0 mg/d, at least the first day, and should be adjusted to kidney function and age with the new French summary of product characteristics (SmPCs). Interestingly French GPs from Auvergne did not stop, at least for 81%, urate lowering therapy (ULT) at time of flare, that is good practice.

In Auvergne, roughly 40% of French GPs use ULT in asymptomatic hyperuricemia (HU), which is not an approved label for allopurinol or febuxostat. Misuse of ULT can lead to serious adverse event with allopurinol or febuxostat, and should be avoided. Again only 50% of persons with initial SUA level > 10.0 mg/dL at base line and followed 10 years developed gout [9,10]. Thus, there is no real good reason to treat nowadays asymptomatic HU.

Indeed the real issue for all recommendations is to find out the proper way to implement these good and simple practical guidelines. It is always difficult to sum up some complicated recommendations such as the ACR ones. They should be reduced in few sentences or quality indicators as we proposed [11]. As any physicians, GPs need to have refreshing courses and CME courses, with referees. Also there is a key point named clinical inertia. Physicians (and patients) might be reluctant to add ULT, or to increase allopurinol dosage for fears and beliefs [11]. In 50% of these situations, physicians are responsible for not adjusting dosage. For sure, the other side of the sword is the patient's attitude and our colleagues refer to “patient education”. Few programs dedicated to gout and patient education have been raised in France. Other pathways for improving patient compliance are developed using e-health devices or only cell phone messages for recalling drug intake.

Indeed the final point to improve guidelines implementation is related to junior doctor or event undergraduate student education; indeed it is the responsibility of educators to implement good practices for gout diagnosis and management, since gout is a real frequent disease in our country (0.9%) compared to other autoimmune diseases, on one hand, and to common diseases such as osteoporosis and osteoarthritis, on the other hand.

Disclosure of interest

JG, H-KE, PG declare that they have no competing interest; FL: institutional grants from Ipsen Pharma, Menarini, Grunenthal Central, SOBI, Mayoly-Spindler, Novartis for the European Crystal Network workshops (Paris); fees for CME and boards.

Brigitte Lanz is an employee of Mayoly-Spindler; Charles Lambert is an employee of Ipsen Pharma.

References

- [1] Mourgues C, Pereira B, Vorilhon P, et al. 2012 American guidelines for the management of gout as seen by general practitioners. *Joint Bone Spine* 2018; <http://dx.doi.org/10.1016/j.jbspin.2018.09.015>.
- [2] Goossens J, Lancrenon S, Lanz S, et al. GOSPEL 3: management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century – comparison with 2006 EULAR Recommendations. *Joint Bone Spine* 2017;84:447–53.
- [3] Zhang W, Doherty M, Bardin T, et al. EULAR standing committee for international clinical studies including therapeutics. EULAR evidence-based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Ann Rheum Dis* 2006;65:1312–24.
- [4] Richette P, Doherty M, Pascual E, et al. 2016 Updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis* 2017;76:29–42.
- [5] Lioté F, Lancrenon S, Lanz S, et al. GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics ($n = 1003$). *Joint Bone Spine* 2012;79:464–70.
- [6] Dalbeth N, Bardin T, Doherty M, et al. Discordant American College of physicians and international rheumatology guidelines for gout management: consensus

- statement of the gout, hyperuricemia and crystal-associated disease network (G-CAN). *Nat Rev Rheumatol* 2017;13:561–8.
- [7] Khanna D, Khanna PP, Fitzgerald JD, et al. American College of rheumatology. 2012 American College of rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. *Arthritis Care Res (Hoboken)* 2012;64:1447–61.
- [8] Pascart T, Lancrenon S, Lanz S, et al. GOSPEL 2 – Colchicine for the treatment of gout flares in France – a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age. *Joint Bone Spine* 2016;83:687–93.
- [9] Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. *Ann Rheum Dis* 2018;77:1048–52.
- [10] Lioté F, Pascart T. From hyperuricaemia to gout: what are the missing links? *Nat Rev Rheumatol* 2018;14:448–9.
- [11] Pascart T, Lioté F. Gout: state of the art after a decade of developments. *Rheumatology (Oxford)* 2018, <http://dx.doi.org/10.1093/rheumatology/key002>.

Julia Goossens^a
 Sylvie Lancrenon^b
 Sabine Lanz^c
 Hang-Korng Ea^{a,d,e}
 Charles Lambert^f
 Pascal Guggenbuhl^{g,h,i}
 Alain Saraux^j
 Catherine Delva^k
 Samy Sahbane^k
 Frédéric Lioté^{a,d,e,*}

^a Service de rhumatologie, hôpital Lariboisière, AP-HP, centre Viggo-Petersen, 75010 Paris, France

^b Sylia-Stat, 92340 Bourg-La-Reine, France
^c Laboratoires Mayoly-Spindler, 78401 Chatou, France
^d University Paris Diderot, Sorbonne Paris cité, 75205 Paris, France
^e Inserm, UMR 1132, centre Viggo-Petersen, 75010 Paris, France
^f Laboratoires Ipsen Pharma, 92100 Boulogne-Billancourt, France
^g Service de rhumatologie, CHU de Rennes, 35203 Rennes, France
^h Inserm, UMR 991, 35000 Rennes, France
ⁱ Faculté de médecine, université Rennes 1, 35043 Rennes, France
^j Service de rhumatologie, CHU de la Cavale-Blanche, université de Bretagne occidentale, 29000 Brest, France
^k Vivactis études cliniques, 92400 Courbevoie, France

* Corresponding author at: Service de rhumatologie, hôpital Lariboisière, AP-HP, centre Viggo-Petersen, 2, rue Ambroise-Paré, 75010 Paris, France.
 E-mail address: frederic.liote@aphp.fr (F. Lioté)

Available online 3 October 2018